Scroll to the bottom of the page to pay your bill

Surviving Lung Cancer Through Immunotherapy

Immunotherapy in advanced non-small cell lung cancers has helped to extend the overall and progression-free survival in some patients without compromising their quality of life. It forces the immune system to control the disease by fighting cell proliferation. Experts have confirmed that patients who have undergone immunotherapy for NSCLC have survived for longer.

The overall five-year survival rate for advanced non-small cell lung cancer has been less than 5%. But today, a growing proportion of NSCLC patients have lived longer than five years. This indicates that there is a possibility of extending the lives of lung cancer patients using immunotherapies. A randomized trial showed that an average number of patients treated with a single immune therapy (nivolumab) remained alive five years later.

During a study:

 The patients subjected to a trial showed an improvement in survival with more than three years of follow-up with the inhibitor pembrolizumab. During the time of treatment, the patients’ tolerability towards the monotherapy regimen was high. The duration of response was high too, with patients who received pembrolizumab for two years stabilizing with no need for additional therapy.

 Some patients, after getting treatment for two years, also received pembrolizumab as a second course after progression of the disease. This means the cancer cab stabilize after re-exposure.

 When used alongside chemotherapy in patients with stage IV squamous cell NSCLC, immunotherapy, specifically atezolizumab inhibiting agent, would benefit patients.

 Although immunotherapy may not eradicate the tumor in some stages of NSCLC, the disease can be controlled in some cases as seen in this trial.
Researchers may not have identified the features that would help to predict which patients responded to anti-PD-1 therapy during the trial. But they still managed to know the effect of immunotherapy in patients with tumors that had high PD-1 expression.

You Might Also Enjoy...

Are You at Risk for Ovarian Cancer?

It would be great if we had a crystal ball to tell us which illnesses we’ll get and how to avoid them. Until we do, the next best thing is to know your risk factors for certain diseases, including ovarian cancer.

How MammoSite® Therapy Works

After your breast cancer diagnosis, your mind turns immediately to treatments. You want the most effective, least invasive option possible. Here’s why MammoSite® targeted radiation therapy may be the best answer.

How Long Does Hair Loss Last With Chemo or Radiation?

You’d give up almost anything for a chance to beat your cancer. And many treatments will test your resolve to do just that. Hair loss is one of the sacrifices most-often associated with chemo and radiation. Here’s what you can expect.

How Hormone Therapy Works to Combat Cancer

Most people are familiar with radiation and chemotherapy as effective go-to treatments, but there are many more cancer-fighting weapons in our arsenal. Here’s how hormone therapy may be a key player in your cancer treatment plan.